Journal Mobile Options
Table of Contents
Vol. 82, No. 3, 2009
Issue release date: May 2009

Evaluation of Urolithiasis: A Link between Stone Formation and Diabetes Mellitus?

Zimmerer T. · Weiss C. · Hammes H.P. · Braun C. · Hesse A. · Alken P. · Knoll T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Introduction: The pathogenesis of calcium oxalate stone formation is not completely understood. Recently, an influence of vascular phenomena like arteriosclerosis on the crystallization process was hypothesized. Thus, stone formation should be more common in patients with diabetes mellitus (DM) who are at risk of developing angiopathy. The aim of the study was to determine the prevalence of urolithiasis (UL) in patients with DM and to identify specific risk factors. Material and Methods: 350 patients with DM were evaluated with respect to DM-related history, and a total of 179 patients was included (83 female, 96 male; age 23–84 years). All patients were interviewed to assess the history of stone formation. These data were compared to epidemiological data in Germany. Results: The overall prevalence of UL in the diabetic group was 7.82% (vs. 4.73% in Germany, p = 0.0485; binominal test). The prevalence was significantly higher in patients with coronary heart disease (25%; p < 0.0001; Fisher‘s exact test). We could not demonstrate an increased prevalence of UL for patients with occlusive arterial disease or arterial hypertension as diabetic nephropathy was not a risk factor for developing urinary lithiasis (p = 0.7184, p = 1.000, p = 0.6266, respectively; Fisher’s exact test). Thiazide medication lowered the prevalence of stone formation (p = 0.0399; Fisher’s test). Calcium or magnesium supplementation did not influence stone formation significantly (p = 0.5279; p = 1.000; respectively; Fisher’s test). Conclusions: In Germany, patients with DM are at higher risk of UL compared with patients without diabetes. We demonstrated a significantly higher prevalence of urinary stones in patients with coronary heart disease. These findings are consistent with the hypothesis that urinary stone formation has a vascular pathogenesis in part.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Strohmaier WL: Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi. Urologe A 2000;39:166–170.
  2. Hesse A, Brandle E, Wilbert D, Kohrmann KU, Alken P: Study on the prevalence and incidence of urolithiasis in Germany comparing years 1979 vs. 2000. Eur Urol 2003;44:709–713.
  3. Kok DJ: Crystallization and stone formation inside the nephron. Scan Microsc 1996;10:471–481.
  4. Khan SR, Byer KJ, Thamilselvan S, Hackett RL, McCormack WT, Benson NA, Vaughn KL, Erdos GW: Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J Am Soc Nephrol 1999;10(suppl 14):457–463.
  5. Verkoelen CF, van der Boom BG, Houtsmuller AB, Schroder FH, Romjin JC: Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol 1998;274: F958–F965.
  6. Lieske JC, Spargo BH, Toback FG: Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol 1992;148:1517–1519.
  7. de Water R, Noordermeer C, Houtsmuller AB, Nigg AL, Stijnen T, Schroder FH, Kok DJ: Role of macrophages in nephrolithiasis in rats: an analysis of the renal interstitium. Am J Kidney Dis 2000;36:615–625.
  8. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M: Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loop of Henle. J Clin Invest 2003;111:607–616.
  9. Stoller ML, Meng MV, Abrahams HM, Kane JP: The primary stone event: a new hypothesis involving a vascular etiology. J Urol 2004;171:1920–1924.
  10. Sampaio FJB, Aragap AHM: Anatomical relationship between the intrarenal arteries and the kidney collecting system. J Urol 1990;143:679.
  11. Bushinsky DA, Monk RD: Electrolyte quintet: calcium. Lancet 1998;352:306–311.
  12. Meydan N, Barutca S, Caliskan S, Camsari T: Urinary stone disease in diabetes mellitus. Scand J Urol Nephrol 2004;37:64–70.

    External Resources

  13. Rosner B: Fundamentals of Biostatistics, ed 4, section 7.10.3. Pacific Grove, Duxbury Press, 1999.
  14. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
  15. Harris MI, Klein R, Welborn TA, Knuiman MW: Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care 1992;15:815–819.
  16. Akinci M, Esen T, Tellaloglu S: Urinary stone disease in Turkey: an updated epidemiological study. Eur Urol 1991;20:200–203.
  17. Oner A, Demircin G, Ipekcioglu H, Bulbul M, Ecin N: Etiological and clinical patterns of urolithiasis in Turkish children. Eur Urol 1997;31:453–458.
  18. al-Hadramy MS: Seasonal variations of urinary stone colic in Arabia. J Pak Med Assoc 1997;47:281–284.

    External Resources

  19. Taylor EN, Stampfer MJ, Curhan GC: Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005;68:1230–1235.
  20. Daudon M, Traxer O, Conort P, Lacour B, Jungers P: Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006;17:2026–2033.
  21. Glowacki LS, Beecroft ML, Cook RJ, Pahl D, Churchill DN: The natural history of asymptomatic urolithiasis. J Urol 1992;147:319–321.
  22. Nishio S, Yokoyama M, Iwata H, et al: Obesity as one of the risk factors for urolithiasis. Nippon Hinyokika Gakkai Zasshi 1998;89:573–580.
  23. Curhan GC, Willet WC, Rimm EB, Speizer FE, Stampfer MJ: Body size and risk of kidney stones. J Am Soc Nephrol 1998;9:1645–1652.
  24. Siener R, Glatz S, Nicolay C, Hesse A: The role of overweight and obesity in calcium oxalate stone formation. Obes Res 2004;12:106–113.
  25. el-Hazmi MA, Warsy AS: Prevalence of overweight and obesity in diabetic and non-diabetic Saudis. East Mediterr Health J 2000;6:276–282.

    External Resources

  26. Fleming DE, Van Riessen A, Chauvet MC, Grover PK, Hunter B, Van Bronswijk W, Ryall RL: Intracrystalline proteins and urolithiasis: a synchrotron X-ray diffraction study of calcium oxalate monohydrate. J Bone Miner Res 2003;18:1282–1291.
  27. Fraij BM: Separation and identification of urinary proteins and stone-matrix proteins by mini-slab sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Clin Chem 1989;35:658–662.
  28. Cerini C, Geider SM, Dussol B, et al: Nucleation of calcium oxalate crystals by albumin: Involvement in the prevention of stone formation. Kidney Int 1999;55:1776.
  29. Grover PK, Moritz RL, Simpson RJ, Ryall RL: Inhibition of growth and aggregation of calcium oxalate crystals in vitro: a comparison of four human proteins. Urol J Biochem 1998;253:637–644.
  30. Verkoelen CF, Schepers MS: Changing concepts in the aetiology of renal stones. Curr Opin Urol 2000;10:539–544.
  31. Stapleton AM, Seymour AE, Brennan JS, et al: Immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int 1993;44:817–824.
  32. Grandaliano G, Gesualdo L, Schena FP: Thrombin: a novel renal growth factor. Exp Nephrol 1999;7:20–25.
  33. Deuel TF, Kawahara RS, Mustoe TA, Pierce AF: Growth factors and wound healing: platlet-derived growth factor as a model cytokine. Annu Rev Med 1991;42:567–584.
  34. Hamano S, Nakatsu H, Suzuki N, Tomioka S, Tanaka M, Murakami S: Kidney stones disease and risk factors for coronary heart disease. Int J Urol 2005;12:859–863.
  35. Mancia G: The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005;42(suppl 1):17–25.

    External Resources

  36. Waeber B, Feihl F, Ruilope L: Diabetes and hypertension. Blood Press 2001;10:311–321.
  37. Woelfel A, Kaplan RA, Pak CY: Effect of hydrochlorothiazide therapy on the crystallization of calcium oxalate in urine. Metabolism 1977;26:201–205.
  38. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A: Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002;346:77–84.
  39. von Unruh GE, Voss S, Sauerbruch T, Hesse A: Dependence of oxalate absorption on the daily calcium intake. Am Soc Nephrol 2004;15:1567–1573.
  40. Ekeruo WO, Tan YH, Young MD, Dahm P, Maloney ME, Mathias BJ, Albala DM, Preminger GM: Metabolic risk factors and the impact of medical treatment on the management of nephrolithiasis in obese patients. J Urol 2004;172:159–163.
  41. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K: The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004;65:386–392.
  42. Pak CYC, Sakhaee K, Moe O, Preminger GM, Poindexter JR, Peterson RD, Pietrow P, Ekeruo W: Biochemical profile of stone-forming patients with diabetes mellitus. Urology 2003;61:523–527.
  43. Coe FL, Kavalach AG: Hyperclacuria and hyperuricusuria in patients with calcium nephrolithiasis. N Engl J Med 1974;291:1344–1350.
  44. Pak CYC, Waters O, Arnold L, et al: Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. J Clin Invest 1977;59:426–431.
  45. Embon OM, Rose GA, Rosenbaum T: Chronic dehydration stone disease. Br J Urol 1990;66:357–362.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50